celecoxib + exemestane

Celecoxib + exemestane is a combination of two small molecule drugs used in clinical research for the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), primarily used for its analgesic, anti-inflammatory, and antipyretic properties. It inhibits prostaglandin synthesis by selectively blocking COX-2, reducing inflammation and pain; it also has demonstrated anticancer effects through additional mechanisms such as binding to cadherin-11 and inhibiting 3-phosphoinositide-dependent kinase 1 (PDK1)[3][6][8]. Exemestane is an irreversible steroidal aromatase inhibitor that blocks the conversion of androgens to estrogens by covalently binding to the aromatase enzyme ("suicide" inhibition), leading to estrogen deprivation in hormone-sensitive tumors[4]. The combination has been studied in neoadjuvant settings for breast cancer with evidence suggesting tolerability and potential anti-tumor activity[1][2][3][5].

Other names

none